



Customer No. 36441

PTO/SB/21 (03-03)
Approved for use through 4/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/619,253	
	Filing Date	July 15, 2003	
	First Named Inventor	Crooke et al	
	Group Art Unit		
	Examiner Name		
Total Number of Pages in this Submission	12	Attorney Docket Number	ISPH-0590US.P1

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to a Technology Center <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below):
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual Name	Mary E. Bak HOWSON AND HOWSON
Signature	<i>Mary E. Bak</i>
Date	<i>Oct. 8, 2003</i>

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this date: _____			
Typed or printed name	Janet Larson		
Signature	<i>Janet Jan</i>	Date	<i>10/08/2003</i>

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



ISPH-0590US.P1

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appln. No. : 10/619,253 Confirmation No.:
Applicant : ISIS Pharmaceuticals, Inc.
Filed: : July 15, 2003
TC/A.U. :
Examiner :
Customer No. : 36441
Title : ANTISENSE MODULATION OF STEAROYL COA
DESATURASE EXPRESSION

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicant submits to the Examiner the attached Form PTO/SB/08A/B document listing and this paper pursuant to 37 CFR § 1.56 and § 1.97-1.98. Form PTO/SB/08A/B and this paper identify documents previously cited in US Patent Application No. 09/918,187, filed July 30, 2001.

Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450.

on 10/8/2003
Janet Larson
Signature
Janet Larson

According to 37 CFR § 1.98(d), Applicant has not enclosed copies of any US patents, publications, or other documents listed herein, which listed items were previously cited by or submitted to the US Patent and Trademark Office in prior parent US Patent Application No. 09/918,187, filed July 30, 2001. The prior parent patent application is relied upon herein for an earlier priority date under 35 USC § 120.

The Director is hereby authorized to charge any deficiency in any fees due with the filing of this paper or credit any overpayment in any fees to our Deposit Account Number 08-3040.

REMARKS

Listed below is a previously filed, and co-pending, US patent application. This application and the present application are commonly owned.

US Patent Application No. 09/918,187, filed July 30, 2001

(US Patent Publication No. US-2003-0083282-A1, published May 1, 2003)

Listed below are documents cited in the International Search Report dated April 16, 2003 in the related International Patent Application No. PCT/US02/22676, filed July 16, 2003. A copy of the Report is enclosed.

AB US Patent No. 5,801,154, issued September 1, 1998
AN International Patent Publication No. WO-00/09754, published 02-24-2000

AAW MILNER et al., "Selecting Effective Antisense Reagents on Combinatorial Oligonucleotide Arrays", Nature Biotechnol., 15:537-541 (June 1997)


The month of publication for documents AT, AW, and AAU could not be determined. The years of publication for documents AT and AW are sufficiently earlier than the effective US filing date and/or the foreign priority date of the present application so that the particular month of publication of the documents is not in issue (MPEP 609).

The Examiner is respectfully requested to consider the enclosed document identified in this paper and in the attached Form PTO/SB/08A/B during the course of examination of this application.

Respectfully submitted,

HOWSON AND HOWSON
Attorneys for Applicant

By Mary E. Bak
Mary E. Bak
Registration No. 31,215
Spring House Corporate Center
Box 457
Spring House, PA 19477
(215) 540-9200



PTO/SB/08a (06-03)
Approved for use through 4/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/619,253
				Filing Date	July 15, 2003
				First Named Inventor	Crooke et al.
				Group Art Unit	
				Examiner Name	
Sheet	1	of	4	Attorney Docket Number	ISPH-0590US.P1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA	US-2002-0151018	10-17-2002	PROUTY et al.	
	AB	US-5,801,154	09-01-1998	BARACCHINI et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ -Kind Code ⁵ (if known)				
	AL	EP-238 198-A2	09-23-1987	CHAVALI et al.		
	AM	WO-99/63979	12-16-1999	HABIB NAGY ADLY		
	AN	WO-00/09754	02-24-2000	JOHNSON & JOHNSON		

Examiner Signature		Date Considered	
--------------------	--	--------------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by Translation is attached. ⁶ Applicant is to place a check mark here if English language

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS.
SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08b (06-03)
Approved for use through 6/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/619,253
				Filing Date	July 15, 2003
				First Named Inventor	Crooke et al.
				Group Art Unit	
				Examiner Name	
Sheet	2	of	4	Attorney Docket Number	ISPH-0590US.P1

NONPATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	AR	BENE et al., "Cloning and Characterization of the Human Stearoyl-CoA Desaturase Gene Promoter: Transcriptional Activation by Sterol Regulatory Element Binding Protein and Repression by Polyunsaturated Fatty Acids and Cholesterol", Biochem. and Biophys. Res. Commun., 284:1194-1198 (June 29, 2001)	
	AS	DIOT et al., "Stearoyl-CoA Desaturase 1 Coding Sequences and Antisense RNA Affect Lipid Secretion in Transfected Chicken LMH Hepatoma Cells", Arch. Biochem. Biophys., 380 (2):243-250 (August 15, 2000)	
	AT	JONES et al., "Adipose Tissue Stearoyl-CoA Desaturase mRNA is Increased by Obesity and Decreased by Polyunsaturated Fatty Acids", Am. J. Phys. 271(1):E44-E49 (1996)	
	AU	KIM et al., "Differential Regulation of the Stearoyl-CoA Desaturase Genes by thiazolidinediones in 3T3-L1 Adipocytes", J. Lipid. Res. 41:1310-1316 (August 2000)	
	AV	LI et al., "Partial Characterization of a cDNA for Human Stearoyl-CoA Desaturase and Changes in its mRNA Expression in Some Normal and Malignant Tissues", Int. J. Cancer, 57:348-352 (May 1, 1994)	
	AW	NTAMBI, "The Regulation of Stearoyl-CoA Desaturase (SCD)", Prog. Lipid. Res., 34(2):139-150 (1995)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08b (06-03)
Approved for use through 6/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/619,253
				Filing Date	July 15, 2003
				First Named Inventor	Crooke et al.
				Group Art Unit	
				Examiner Name	
Sheet	3	of	4	Attorney Docket Number	ISPH-0590US.P1

NONPATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	AX	SESSLER et al., "Regulation of Stearoyl-C-A Desaturase 1 mRNA Stability by Polyunsaturated Fatty Acids in 3T3-L1 Adipocytes", J. Biol. Chem., 271(47):29854-29858 (November 22, 1996)	
	AY	SINGH et al., "Differential Effects of Rexinoids and thiazolidinediones on Metabolic Gene Expression in Diabetic Rodents", Mol. Pharmacol., 59:765-773 (April 2001)	
	AZ	ZHANG et al., "Human Stearoyl-Co-A Desaturase: Alternative Transcripts Generated from a Single Gene by Usage of Tandem Polyadenylation sites", Biochem. J., 340:255-264 (May 15, 1999)	
	AAR	ZHANG et al., "Isolation and Characterization of the Human Stearoyl-CoA Desaturase Gene Promoter: Requirement of a Conserved CCAAT cis-Element", Biochem. J. 357:183-193 (July 1, 2001)	
	AAS	AGRAWAL et al., "Antisense Therapeutics: Is it as Simple as Complementary Base Recognition?", Mol. Med. Today, 6:72-81 (February 2000)	
	AAT	GREEN et al., "Antisense Oligonucleotides: An Evolving Technology for the Modulation of Gene Expression in Human Disease", 191(1):93-105 (July 2000)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	4	of	4	Attorney Docket Number	ISPH-0590US.P1
-------	---	----	---	------------------------	----------------

NONPATENT LITERATURE DOCUMENTS

[illegible]

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.